Review
References
|
Aderounmu F, Salako L, Lindström B, Walker O, Ekman L (1986). Comparison of the pharmacokinetics of chloroquine after single intravenous and intramuscular administration in healthy Africans. Br. J. Clin. Pharmacol. 22(1):559-564. |
|
|
Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flanagan CL (1990). Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J. Lab. Clin. Med. 46(1):301-306. |
|
|
Back DJ, Purba HS, Staiger C, Orme ML, Breckenridge AM (1983a). Inhibition of drug metabolism by the antimalarial drugs chloroquine and primaquine in the rat. Biochem. Pharmacol. 32(2):257-263. |
|
|
Back DJ, Purba HS, Park BK, Ward SA, Orme ML (1983b). Effect of chloroquine and primaquine on antipyrine metabolism. Br. J. Clin. Pharmacol. 16(5):497-502. |
|
|
Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF (2013). Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N. Engl. J. Med. 369(1):1381-1382. |
|
|
Bhatia SC, Saraph YS, Revankar SN, Doshi KJ, Bharucha ED, Desai ND, Vaidya AB, Subrahmanyam D, Gupta KC, Satoskar RS (1986).Pharmacokinetics of primaquine in patients with P. vivax malaria. Eur. J. Clin. Pharmacol. 31(1):205-210. |
|
|
Bureau of Vector Borne Diseases DoDC, Ministry of Health. National Strategic Plan for Malaria Control and Elimination in Thailand, 2015. |
|
|
Congpuong K, Na-Bangchang K, Thimasarn K, Tasanor U, Wernsdorfer WH (2002). Sensitivity of Plasmodium vivax to chloroquine in SaKaeo Province, Thailand. Acta Trop. 83:117-121. |
|
|
Constantino L, Paixão P, Moreira R, Portela MJ, Do Rosario VE, Iley J (1999). Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine. Exp. Toxicol. Pathol. 51(4-5):299-303. |
|
|
Cuong BT, Binh VQ, Dai B, Duy DN, Lovell CM, Rieckmann KH,Edstein MD (2006). Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? Br. J. Clin. Pharmacol. 61(1):682-689. |
|
|
Ducharme J, Farinotti R (1996). Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin. Pharmacokinet. 31(4):257-274. |
|
|
Edwards G, Davies A, Phillips RE, Looareesuwan S, Karbwang J, White NJ, Warrel DA (1987). Plasma concentrations and toxicity of chloroquine after slow intravenous infusion in patients with falciparum malaria. Ann. Trop. Med. Parasitol. 81(1):79-84. |
|
|
Edwards G, Looareesuwan S, Davies AJ, Wattanagoon Y, Phillips RE, Warrell DA (1988). Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. Br. J. Clin. Pharmacol. 25(4):477-485. |
|
|
Edwards G, McGrath CS, Ward SA, Supanaranond W, Pukrittayakamee S, Davis TM, White NJ (1993). Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. Br. J. Clin. Pharmacol. 35(1):193-198. |
|
|
Elmes NJ, Mennett SM, Abdalla H, Carthew TL, Edstein MD (2006). Lack of sex effect on the pharmacokinetics of primaquine. Am. J. Trop. Med. Hyg. 74(1):951-952. |
|
|
Fletcher KA, Evans DA, Gilles HM, Greaves J, Bunnag D, Harinasuta T (1981). Studies on the pharmacokinetics of primaquine.Bull. World Health Organ.59(3):407-412. |
|
|
Fletcher KA, Barton PF, Kelly JA (1988). Studies on the mechanisms of oxidation in the erythrocyte by metabolites of primaquine. Biochem. Pharmacol. 37(13):2683-2690. |
|
|
Frisk-Holmberg M, Bergqvist Y, Termond E, Domeij-Nyberg B (1984). The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects. Eur. J. Clin. Pharmacol. 26(4):521-530. |
|
|
Greaves J, Evans DA, Gilles HM, Fletcher KA, Bunnag D, Harinasuta T (1980). Plasma kinetics and urinary excretion of primaquine in man. Br. J. Clin. Pharmacol. 10(4):399-404. |
|
|
Gustafsson LL, Walker O, Alván G, Beermann B, Estevez F, Gleisner L, Lindström B, Sjöqvist F (1983). Disposition of chloroquine in man after single intravenous and oral doses. Br. J. Clin. Pharmacol. 15(4):471-479. |
|
|
Gustafsson LL, Lindström B, Grahnén A, Alván G (1987). Chloroquine excretion following malaria prophylaxis. Br. J. Clin. Pharmacol. 24(2):221-224. |
|
|
Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W, Chotsiri P, Wattanakul T, Panapipat S, Lee SJ, Day NP (2014). Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Antimicrob. Agents Chemother. 58(12):7340-7346. |
|
|
Höglund R, Moussavi Y, Ruengweerayut R, Cheomung A, Äbelö A, Na-Bangchang K (2016). Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border. Malar. J. 15:129. |
|
|
Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B, Binh TQ, Thu le TA, Hung NC, Pirmohamed M, Park BK, Edwards G (2002). Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab.Dispos. 30(9):1005-1012. |
|
|
Jittamala P, Pukrittayakamee S, Ashley EA, Nosten F, Hanboonkunupakarn B, Lee SJ, Thana P, Chairat K, Blessborn D, Panapipat S, White NJ (2015). Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Antimicrob. Agents Chemother. 59(1):505-513. |
|
|
Jin X, Pybus BS, Marcsisin SR, Logan T, Luong TL, Sousa J, Matlock N, Collazo V, Asher C, Carroll D, Olmeda R, Walker LA, Kozar MP, Melendez V (2014). An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model. Eur. J. Drug Metab. Pharmacokinet. 39(1):139-146. |
|
|
Karbwang J, Harinasuta T (1992). Overview: clinical pharmacology of antimalarials.Southeast Asian J. Trop. Med. Public Health. 23 Suppl 4:95-109. |
|
|
Karunajeewa HA, Ilett KF, Mueller I, Siba P, Law I, Page-Sharp M, Lin E, Lammey J, Batty KT, Davis TM. (2008). Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob. Agents Chemother. 52(1):237-243. |
|
|
Karunajeewa H, Salman S, Mueller I, Baiwog F, Gomorrai S, Law I, Page-Sharp M, Rogerson S, Siba P, Ilett KF, Davis TM (2010). Pharmacokinetics of chloroquine and monodesethyl-chloroquine in pregnancy. Antimicrob. Agents Chemother. 54(1):1186-1192. |
|
|
Krishna S, White NJ (1996). Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet. 30(4):263-299. |
|
|
Looareesuwan S, White NJ, Chanthavanich P, Edwards G, Nicholl DD, Bunch C, Warrell DA (1986). Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br. J. Clin. Pharmacol. 22(1):31-36. |
|
|
Leang R, Khu NH, Mukaka M, Debackere M, Tripura R, Kheang ST, Chy S, Kak N, Buchy P, Tarantola A, Menard D, Roca-Felterer A, Fairhurst RM, Kheng S, Muth S, Ngak S, Dondorp AM, White NJ, Taylor WR (2016). An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia. BMC Med. 14(1):171. |
|
|
Lee SJ, McGready R, Fernandez C, Stepniewska K, Paw MK, Viladpai-Nguen SJ, Thwai KL, Villegas L, Singhasivanon P, Greenwood BM. and White, N.J (2008). Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria. Eur. J. Clin. Pharmacol. 64:987-992. |
|
|
Li XQ, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa CM (2003). Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur. J. Clin. Pharmacol. 59(5-6):429-442. |
|
|
Mansor SM, Ward SA, Edwards G, Hoaksey PE, Breckenridge AM (1990). The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. J. Pharm. Pharmacol. 42(6):428-432. |
|
|
Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM (1985). Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br. J. Clin. Pharmacol. 19(1):745-750. |
|
|
Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L (2011).Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar. J.10(1):263. |
|
|
Muhamad P, Ruengweerayut R, Chacharoenkul W, Rungsihirunrat K, Na-Bangchang K (2011). Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010. Malar. J. 10(1):44. |
|
|
Na-Bangchang KN, Karbwang J, Back DJ (1992). Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem. Pharmacol. 44(3):587-590. |
|
|
Na-Bangchang K, Limpaibul L, Thanavibul A, Tan-Ariya P, Karbwang J (1994a). The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. Br. J. Clin. Pharmacol. 38(3):278-281. |
|
|
Na-Bangchang K, Songsaeng W, Thanavibul A, Choroenlarp P, Karbwang J (1994b). Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria.Trans. R. Soc.Trop. Med. Hyg. 88(2):220-222. |
|
|
Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, Olliaro P (2000). Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet. 39(4):255-270. |
|
|
Obua C, Hellgren U, Ntale M, Gustafsson LL, Ogwal-Okeng JW, Gordi T, Jerling M (2008). Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. Br. J. Clin. Pharmacol. 65(1):493-501. |
|
|
Pukrittayakamee S, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri S, Lee SJ, Hanpithakpong W, Hanboonkunupakarn B, Day NPJ, Ashley EA, White NJ (2014). Pharmacokinetic interactions between primaquine and chloroquine. Antimicrob Agents Chemother. 58:3354-3359. |
|
|
Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, Vuong C, Sciotti RJ, Reichard GA, Kozar MP, Walker LA, Ohrt C, Melendez V (2012). CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar. J. 11:259. |
|
|
Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard GA, Ockenhouse C, Bennett J, Walker LA, Ohrt C, Melendez V (2013). The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar. J. 12:212. |
|
|
Ringwald P, Eboumbou EC, Bickii J, Basco LK (1999). In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum. Antimicrob. Agents Chemother. 43(6):1525-1527. |
|
|
Riviere JH, Back DJ (1985). Effect of mefloquine on hepatic drug metabolism in the rat: comparative study with primaquine. Biochem. Pharmacol. 34(4):567-571. |
|
|
Singhasivanon V, Sabcharoen A, Attanath P, Chongsuphajaisiddhi T, Diquet B, Turk P (1991). Pharmacokinetics of primaquine in healthy volunteers. Southeast Asian J. Trop. Med. Public Health 22 (4):527-533. |
|
|
Tasanor O, Ruengweerayut R, Sirichaisinthop J, Congpuong K, Wernsdorfer WH, Na-Bangchang K (2006). Clinical-parasitological response and in vitro sensitivity of Plasmodium vivax to chloroquine and quinine on the western border of Thailand. Trans. R. Soc. Trop. Med. Hyg.100(1):410-418. |
|
|
Tett SE, Cutler DJ (1987). Apparent dose-dependence of chloroquine pharmacokinetics due to limited assay sensitivity and short sampling times. Eur. J. Clin. Pharmacol. 31(1):729-731. |
|
|
Titus EO (1989). Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. Ther. Drug Monit. 11(4):369-379. |
|
|
Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungmanee D, Nakavej A, Wongsrichanalai C (2006). In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop. Med. Int. Health 11(1):211-219. |
|
|
Vries PJ, Oosterhuis B, Boxtel C (1994). Single-dose pharmacokinetics of chloroquine and its main metabolite in healthy volunteers. Drug Invest. 8(1):143-149. |
|
|
Ward SA, Mihaly GW, Edwards G, Looareesuwan S, Phillips RE, Chanthavanich P, Warrell DA, Orme ML, Breckenridge AM (1985). Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. Br. J. Clin. Pharmacol.19(6):751-755. |
|
|
Wetsteyn JC, De Vries PJ, Oosterhuis B, Van Boxtel CJ (2012).The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. Br. J. Clin. Pharmacol. 39(6):696-699. |
|
|
White NJ (2007). Cardiotoxicity of antimalarial drugs. Lancet Infect. Dis. 7(8):549-558. |
|
|
World Health Organization. Malaria Report. WHO, Geneva, Switzerland, 2016. |
|
|
Zhao Q, Tensfeldt TG, Chandra R, Mould DR (2014). Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed- dose azithromycin and chloroquine combination tablets. Malar. J. 13(1):36 |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
